Table 2.

Summary of primary and secondary endpoints (mITT Set)

Study endpoints	Ibrexafungerp, n/N (%)	Placebo, n/N (%)	Rate difference (%) (95%CI)	P value
Primary endpoint
Clinical cure at TOC	51.0 (122/239)	25.6 (31/121)	25.3 (15.31, 35.21)	< 0.001
Secondary endpoints
Mycological eradication at TOC	55.6 (133/239)	18.2 (22/121)	37.5 (28.18, 46.88)	< 0.001
Overall response at TOC	33.9 (81/239)	8.3 (10/121)	25.6 (17.84, 33.38)	< 0.001
Clinical improvement at TOC	82.0 (196/239)	48.8 (59/121)	33.2 (23.03, 43.30)	< 0.001
Complete symptom resolution at FU	74.5 (178/239)	39.7 (48/121)	34.8 (24.45, 45.11)	< 0.001

mITT modified intention-to-treat, CI confidence interval, TOC test-of-cure, FU follow-up